scholarly journals Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study

2018 ◽  
Vol 20 (6) ◽  
pp. 545 ◽  
Author(s):  
Ming Shi ◽  
Hao Zeng ◽  
Jin-Ge Zhao ◽  
Jian-Dong Liu ◽  
Peng-Fei Shen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Retrospective Study ◽  
Real World ◽  
Therapeutic Efficacy ◽  
Abiraterone Acetate ◽  
Second Line ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 5028-5028 ◽  
Author(s):  
Simon Chowdhury ◽  
Alison J. Birtle ◽  
Anders Bjartell ◽  
Luis Costa ◽  
Susan Feyerabend ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Registry ◽  
Real World ◽  
Abiraterone Acetate ◽  
Second Line ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Baseline Characteristics ◽  
Clinical Trial Information

5028 Background: The Prostate Cancer Registry is a prospective, international observational study that began in June 2013 and will assess the characteristics and management of > 3000 mCRPC patients (pts) in routine clinical practice for ≤ 3 years. Methods: Data were collected from men with mCRPC irrespective of treatment (tx). This interim analysis reports baseline characteristics, txs and outcomes in pts with ≥ 12-month follow-up receiving second-line mCRPC tx following docetaxel as the only prior mCRPC tx. Results: The most commonly initiated second-line mCPRC txs (n ≥ 50) were abiraterone acetate + prednisone (AAP, n = 177), enzalutamide (ENZ, n = 94), or cabazitaxel (CAB, n = 70). Characteristics and outcomes are shown in the table below. TTP was not significantly different for AAP vs ENZ, AAP vs CAB or ENZ vs CAB (propensity score adjusted p = 0.5954, p = 0.5888 and p= 0.4808, respectively). Conclusions: In this real-world study, clinical outcomes reveal that, in pts receiving second-line mCRPC tx after docetaxel, TTP was similar across tx groups; QoL improved most in AAP and ENZ groups and no deterioration was observed most in AAP and CAB groups. Clinical trial information: NCT02236637. [Table: see text]

scholarly journals Real-world safety profile of abiraterone acetate in patients with castration-resistant prostate cancer and cardiovascular comorbidities: a retrospective, single center study

2017 ◽  
Vol 5 (3) ◽  
pp. 20-24
Author(s):  
Giovanni Fuca ◽  
Elena Verzoni ◽  
Alessia Mennitto ◽  
Michele Prisciandaro ◽  
Raffaele Ratta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Adverse Events ◽  
Real World ◽  
Safety Profile ◽  
Abiraterone Acetate ◽  
Left Ventricular ◽  
Cardiovascular Safety ◽  
Castration Resistant Prostate Cancer ◽  
Cardiovascular Comorbidities ◽  
Castration Resistant

Background: Abiraterone acetate became a referral treatment for metastatic castration-resistant prostate cancer (mCRPC) in a post-docetaxel setting despite a remarkable percentage of cardiovascular adverse events (AEs). As a consequence, the evaluation of cardiovascular safety in patients at risk should be mandatory. We aimed to assess the cardiovascular safety of abiraterone acetate in a real-world series of mCRPC patients treated at our institution. Materials and Methods: We retrospectively included mCRPC patients with at least 1 active cardiovascular comorbidity or risk factor according to the European Society of Cardiology (ESC) guidelines and who started treatment with abiraterone acetate from April 2011 to July 2012. Cardiac assessment with electrocardiogram and echocardiogram was performed at baseline and at treatment discontinuation. AEs were defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Statistical analyses were performed by descriptive statistics as appropriate. Results: We included 51 patients of whom 18% had an ESC score risk for a major cardiovascular event ≥4%. At a median follow-up of 36 months, no cardiac AEs (rhythm abnormalities or left ventricular function decrease) were observed. The most frequent grade 1-2 AE reported was fluid retention (18%) followed by hypertension and asthenia (16%). The most frequent grade 3-4 AEs were asthenia and pruritus/rash. No patients discontinued abiraterone because of toxicity. Conclusions: Abiraterone acetate showed a favorable safety profile in mCRPC patients with cardiovascular comorbidities or risk factors in a post-docetaxel setting, but further studies are needed to confirm our findings and to explore other settings of disease.

Sign in / Sign up

Export Citation Format

Share Document